Professor Neumann has four publications in journals of the JAMA group: one in 1995, one in 2002, one in 2004 and one in 2005.

The publication in 1995 is from the time when the indications for genetic testing for carriership of germline mutations predisposing for MEN 2 was unclear.

In 2002 there was a comment published as a Letter to the Editor regarding biochemical analyses and imaging tests for the diagnosis of pheochromocytoma.

In 2004 a first study on prevalence and penetrance of germline mutations of the genes SDHB and SDHD in patients with pheochromocytoma and paraganglioma was published.

In 2005 a first study on prevalence and penetrance of germline mutations of the gene SDHC pheochromocytoma and paraganglioma was published.

1. Schiavi F, Boedeker CC, Bausch B, Peçzkowska M, Gomez CF, Strassburg T, Pawlu C, Buchta M, Salzmann M, Hoffmann MM, Berlis A, Brink I, Cybulla M, Muresan M, Walter MA, Forrer F, Välimäki M, Kawecki A, Szutkowski Z, Schipper J, Walz MK, Pigny P, Bauters C, Willet-Brozick JE, Baysal BE, Januszewicz A, Eng C, Opocher G, **Neumann HP**; European-American Paraganglioma Study Group.
   Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene.
   JAMA. 2005 Oct 26;294(16):2057-63. Erratum in: **JAMA**. 2006 Feb 8;295(6):628.

2. **Neumann HP**, Pawlu C, Peczkowska M, Bausch B, McWhinney SR, Muresan M, Buchta M, Franke G, Klisch J, Bley TA, Hoegerle S, Boedeker CC, Opocher G, Schipper J, Januszewicz A, Eng C; European-American Paraganglioma Study Group.
   Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations.
   JAMA. 2004 Aug 25;292(8):943-51. Erratum in: **JAMA**. 2004 Oct 13;292(14):1686.

3. **Neumann HP.**
   Imaging vs biochemical testing for pheochromocytoma.
   JAMA. 2002 Jul 17;288(3):314-5; author reply 315. No abstract available.

4. **Neumann HP**, Eng C, Mulligan LM, Glavac D, Zäuner I, Ponder BA, Crossey PA, Maher ER, Brauch H.
   Consequences of direct genetic testing for germline mutations in the clinical management of families with multiple endocrine neoplasia, type II.
   JAMA. 1995 Oct 11;274(14):1149-51.

Hartmut Neumann